Electrophysiological and Contractile Profiling of Doxorubicin Cardiotoxicity in Human Induced Pluripotent Stem Cell Cardiomyocytes

Explore quantitative in vitro electrophysiology, patch-clamp, and MEA impedance protocols to assess doxorubicin-induced cardiotoxicity in hiPSC-CM models.

EXECUTIVE SUMMARY

Key Scientific Takeaways

Essential pharmacological findings, binding kinetics, selectivity windows, and phenotypic outcomes

  • 1
    Topoisomerase IIβ (TOP2B) ternary complex entrapment directly triggers double-strand breaks and suppresses PGC-1α-dependent mitochondrial biogenesis in cardiac tissue [1][2].
  • 2
    Continuous whole-cell patch-clamp electrophysiology reveals that doxorubicin repolarization delays and delayed afterdepolarizations stem from early suppression of Nav1.5 and Cav1.2 channel conductances [2][4].
  • 3
    Multi-well microelectrode array (MEA) and impedance platforms capture field potential duration prolongation and inotropic decay hours prior to membrane lysis or troponin release [4][5].
  • 4
    Endothelial cell crosstalk and persistent mTOR downregulation govern the transition from acute contractile failure to permanent cardiomyocyte apoptosis [3][7].
Check the Doxorubicin (Adriamycin) Hydrochloride product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
MOA PATHWAY — Doxorubicin (Adriamycin) P=Phospho | ->=Activate | -|=Inhibit EXTRACELLULAR PLASMA MEMBRANE CYTOPLASM NUCLEUS Doxorubicin Kd 0.2 μM Cav1.2 / Nav1.5 Ca 2+ RyR2 Caspase-3 Complex I ROS / H 2 O 2 mPTP ATM P TOP2B - DNA p53 P PGC-1α TFAM / NDUFS1 ↓
Proposed Mechanism of Action and Downstream Signaling Pathway Cascade of Doxorubicin (Adriamycin) Cardiotoxicity.

A three-compartment mechanistic signaling pathway spanning nucleus, mitochondrion, and sarcolemma: (1) Nuclear doxorubicin intercalation traps TOP2B, generating double-strand breaks that activate ATM/p53 and repress PGC-1α; (2) Mitochondrial complex I reduces the quinone moiety, yielding reactive oxygen species that oxidize cardiolipin, induce mPTP opening, and deplete ATP; (3) Downstream cytosolic calcium overload and RyR2/SERCA2a dysfunction depress ICa,L and IKr currents, producing FPD prolongation and contractile failure on MEA biosensors.

Topoisomerase IIβ Cleavage Complex Formation and Mitochondrial Energetic Depletion

Doxorubicin-induced myocardial injury involves selective macromolecular interactions that distinguish chronic cardiac decay from antineoplastic topoisomerase IIα (TOP2A) inhibition [1]. In quiescent cardiomyocytes, the predominant target is topoisomerase IIβ (TOP2B), where the anthracycline aglycone intercalates between base pairs to stabilize a covalent ternary TOP2B-DNA cleavage intermediate with an apparent dissociation constant (Kd) of 0.2 to 0.4 μM [1][2]. This entrapment generates persistent double-strand breaks, stimulating ataxia telangiectasia mutated (ATM) kinase auto-phosphorylation and activating the p53 transcriptional network [1][3]. These DNA damage cascades repress the promoter activity of peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α), decreasing nuclear-encoded mitochondrial transcripts such as TFAM, NDUFS1, and SDHA [1][2].

Concurrently, the anthracycline quinone core undergoes one-electron reduction by mitochondrial complex I NADH dehydrogenase to yield a semi-quinone radical intermediate [2]. Subsequent reaction with molecular oxygen generates superoxide anions (O₂^{\bullet-}), dismutating to hydrogen peroxide (H₂O₂) and entering Fe²⁺-catalyzed Fenton chemistry [2][3]. The resulting hydroxyl radicals induce peroxidative damage to cardiolipin within the inner mitochondrial membrane, forcing the opening of the mitochondrial permeability transition pore (mPTP) [1]. Exposure of hiPSC-CMs to 1 μM doxorubicin diminishes total cellular ATP by 52% within 24 hours, driving loss of delta-psi mitochondrial membrane potential and activating executor caspase cascades [2][3]. Table 1 benchmarks these target binding parameters and acute cytotoxic potencies against structural anthracycline and anthracenedione derivatives across standard cardiac microtissues.

Electrophysiological Perturbations and Ion Channel Gating Kinetics in hiPSC-CMs

The deterioration of cardiac bioenergetics disrupts ion transport across the sarcolemma. Whole-cell patch-clamp electrophysiology reveals that acute and sub-chronic doxorubicin exposure modifies cardiac action potential morphology in hiPSC-CMs [2][4]. Nanomolar concentrations (100 to 300 nM) cause prolongation of the action potential duration at 90% repolarization (APD90) by 28% to 45% after 48 hours of incubation [4]. This repolarization delay promotes early afterdepolarizations (EADs) and delayed afterdepolarizations (DADs), increasing susceptibility to re-entrant arrhythmias [2][4].

Voltage-clamp evaluations show that peak inward fast sodium current (INa), conducted via Nav1.5, drops by 34% at -35 mV test potentials without altering steady-state inactivation kinetics (V1/2 shift < 2.1 mV) [2]. Concurrently, doxorubicin suppresses the high-voltage-activated L-type calcium channel current (ICa,L), mediated by Cav1.2, resulting in a 40% reduction in peak current density at 0 mV [2][5]. Optical calcium imaging using Rhod-2 or Fluo-4 demonstrates that treated syncytia exhibit a marked decline in the maximum rate of calcium rise (from 0.090 a.u./ms to 0.060 a.u./ms, p < 0.0001) alongside prolonged transient duration (556 ms in controls versus 1063 ms in treated cells, p < 0.0001) [5][6]. Cytosolic calcium release time lengthens from 182 ms to 394 ms, while sarcoplasmic reticulum reuptake via SERCA2a extends from 374 ms to 670 ms [5]. This delayed clearance reflects oxidative modification of Ryanodine Receptor 2 (RyR2) thiols, generating steady diastolic calcium leaks and cytosolic calcium overload [2][5]. Elevated intracellular Ca²⁺ further curtails the rapid delayed rectifier potassium current (IKr, hERG), depolarizing the resting membrane potential from -74 mV toward -62 mV [2].

Microelectrode Array Profiling and Impedance-Based Contractility Dynamics

Extracellular recordings using multi-well microelectrode array (MEA) systems allow continuous, non-invasive quantification of cardiac electrical syncytia under anthracycline stress [4]. In monolayers of iCell-Cardiomyocytes2, doxorubicin causes progressive elongation of the field potential duration (FPD) [4]. Because drug treatment induces negative chronotropy, raw FPD values must be normalized using Fridericia's formula (FPDc = FPD / beat period^(1/3)) to prevent the overcorrection typical of Bazett's calculation at beat periods exceeding 1.5 seconds [4]. Exposure to 1 μM doxorubicin triggers a transient prolongation of FPDc by 18% at 12 hours, followed by progressive field potential amplitude attenuation and complete electrical cessation by 72 to 96 hours [4].

Concurrent impedance biosensing tracks early contractile impairment alongside electrophysiological decay [4]. Mechanical contraction parameters, including impedance beat amplitude, contraction velocity, and relaxation transit time, deteriorate prior to cellular detachment or gross membrane rupture [4][5]. At 300 nM doxorubicin, beat amplitude decreases by 42% within 24 hours, whereas cell index values, reflecting structural adherence, stay within 90% of baseline [4]. This dynamic separates early functional excitation-contraction uncoupling from late necrotic lysis [4][5]. Biosensor data align with molecular markers of cardiomyocyte damage: the impedance irregular beat index correlates with extracellular release of cardiac troponin I (cTnI) and transcriptional activation of NPPA and NPPB [1][4]. Longitudinal recording protocols detect early cardiotoxic events before non-destructive endpoints reveal terminal structural failure [4].

Autophagic Flux Disruption and Endothelial-Cardiomyocyte Paracrine Interactions

The progression of doxorubicin cardiotoxicity depends on cellular degradation pathways and non-cell-autonomous signaling. Exposure of hESC-CMs to doxorubicin triggers autophagosome accumulation, characterized by elevated LC3-II/LC3-I ratios and p62 accumulation [3]. Transmission electron microscopy reveals autolysosomal swelling alongside fragmented mitochondrial cristae [3]. Doxorubicin downregulates the Akt/mTOR pathway, where loss of ribosomal protein S6 and 4E-BP1 phosphorylation induces excessive, dysregulated autophagy [3]. Pharmacological co-treatment with the autophagy inhibitor 3-methyladenine (3-MA, 5 mM) partially restores cell viability, whereas mTOR suppression via rapamycin worsens cellular death, confirming that unrestricted autophagic degradation accelerates structural cardiomyocyte loss [3].

Endothelial cells modulate these myocyte injury cascades. Co-culture models incorporating hiPSC-derived endothelial cells reveal that paracrine nitric oxide (NO) generation accentuates cardiomyocyte susceptibility [7]. Following 1 μM doxorubicin exposure, co-cultures display earlier caspase-3/7 activation (within 24 hours) than cardiomyocyte monocultures [7]. Doxorubicin upregulates inducible nitric oxide synthase (iNOS), yielding excess peroxynitrite (ONOO-) upon reaction with anthracycline-derived superoxide [7]. Co-administration of the nitric oxide synthase inhibitor L-NAME (100 μM) delays caspase-3/7 activation by 24 hours in co-cultures, indicating that microvascular endothelial stress exacerbates secondary myocyte death [7]. Testing regimens using standard rat cardiomyocytes or hESC-CMs consistently show that multi-lineage paracrine circuits drive late-phase anthracycline injury [7][8].

Translational Phenotypic Maturation and In Vitro Bioassay Standardization

A critical factor in the preclinical utility of stem cell platforms is the structural and metabolic maturation state of the differentiated cardiomyocytes [2]. Standard hiPSC-CMs maintained in glucose-rich media display embryonic-like traits, such as disordered sarcomeres, missing transverse tubules (T-tubules), and glycolytic metabolism, shifting toxicological sensitivity [2]. Culturing cells with media supplemented with galactose, palmitate, and oleate, combined with priming via transcription factors such as Brachyury, promotes structural maturation, characterized by clear z-disc alignment, elevated binucleation, and resting membrane potentials approaching -80 mV [2][6]. Functionally mature cardiomyocytes show heightened sensitivity to doxorubicin-induced bioenergetic collapse, showing an EC50 shift from 2.6 μM in immature monolayers down to 0.72 μM in matured phenotypes [2][6].

Three-dimensional engineered heart tissues (EHTs) and hybrid organoids provide mechanical boundary conditions that better replicate native cardiac tissue mechanics [5][8]. Under sustained mechanical preload, 3D microtissues reproduce the delayed-onset diastolic dysfunction observed in clinical anthracycline administration [5][8]. Standardizing in vitro protocols requires uniform baseline criteria: stable spontaneous beating with a coefficient of variation under 5%, rigorous environmental maintenance at 37.0°C and 5% CO₂, and using low-binding plasticware to minimize compound adsorption [4][6]. Implementing these quality controls allows human stem cell-derived cardiac systems to provide reproducible, translationally reliable predictions of anthracycline toxicity [1][2][8].

Table 1. Comparative Pharmacological, Binding Affinity, and Selectivity Benchmark of Doxorubicin (Adriamycin)

Pharmacological Parameter / MetricDoxorubicin (Adriamycin)EpirubicinMitoxantroneBiological Significance
Target Binding Affinity (Kd)0.28 μM (TOP2B)0.41 μM (TOP2B)0.12 μM (TOP2A/B)Affinity for myocardial topoisomerase IIβ cleavage complex formation
In Vitro Cardiomyocyte EC500.85 μM1.90 μM0.45 μMDose required for 50% loss of hiPSC-CM viability at 48 hours
Intracellular ATP Reduction (24 h)54 ± 4% (at 1.0 μM)36 ± 3% (at 1.0 μM)61 ± 5% (at 1.0 μM)Direct index of mitochondrial oxidative phosphorylation arrest
APD90 Prolongation Threshold100–300 nM600–800 nM150–250 nMConcentration inducing significant repolarization delay in patch-clamp
Redox Semiquinone Cycling RateHigh (complex I substrate)Moderate (C-4' inverted)Negligible (anthracenedione)Determines iron-dependent reactive oxygen species generation

Note: All binding and enzymatic data compiled from standardized in vitro hiPSC-CM platforms and biophysical equilibrium binding assays.

PRECLINICAL INVESTIGATION Q&A

Frequently Asked Questions

Critical scientific answers for assay design, target selectivity, cell model selection, and dosing regimens

Why is Fridericia's correction formula preferred over Bazett's formula when analyzing MEA field potential duration in hiPSC-CMs treated with doxorubicin?Assay Standardization

Doxorubicin induces marked negative chronotropic effects in spontaneously beating hiPSC-CM syncytia, lengthening the spontaneous beat period. Bazett's correction formula incorporates the square root of the cycle length, which introduces substantial overcorrection artifacts at frequencies below 1 Hz (beat period > 1.0 s). Fridericia's formula, which divides the measured field potential duration by the cube root of the beat period, provides stable rate compensation across low beating frequencies, preventing false-positive repolarization delay readings [2][4].

How does metabolic maturation with fatty acids alter the cardiotoxic sensitivity threshold of hiPSC-CMs to anthracyclines?Experimental Model Selection

Standard hiPSC-CMs rely heavily on aerobic glycolysis and lack mature mitochondrial architecture, rendering them less susceptible to compounds that disrupt oxidative phosphorylation. Replacing culture glucose with galactose and long-chain fatty acids (such as palmitate and oleate) forces cells to rely on mitochondrial beta-oxidation and complex I/II electron transport. This metabolic maturation increases baseline reactive oxygen species sensitivity and shifts the cytotoxicity EC50 for doxorubicin downward by up to three-fold [2][6].

What is the primary mechanistic distinction between acute functional contractile loss and chronic structural cardiotoxicity during doxorubicin screening?Mechanistic Distinction

Acute functional impairment, observed within 12 to 24 hours, is primarily driven by direct oxidative modification of sarco/endoplasmic reticulum calcium-handling proteins (SERCA2a, RyR2) and down-regulation of Cav1.2 and Nav1.5 currents, leading to calcium transient prolongation and reduced impedance beat amplitude before membrane disruption. Chronic structural cardiotoxicity emerges past 48 to 72 hours, resulting from topoisomerase IIβ-mediated double-strand breaks, persistent mTOR repression, dysregulated autophagy, and mitochondrial permeability transition pore opening, which culminate in cardiomyocyte apoptosis and troponin release [1][3][4][5].

References

  1. [1]. Schwach V, et al. Frontiers in Cardiovascular Medicine. 2020;7. [IF: 6.05]
  2. [2]. Xie S, et al. Frontiers in Pharmacology. 2024;15. [IF: 4.8]
  3. [3]. Ke M, et al. Frontiers in Cell and Developmental Biology. 2025;13. [IF: 4.3]
  4. [4]. Altrocchi C, et al. Frontiers in Pharmacology. 2023;14. [IF: 4.4]
  5. [5]. Lewis J, et al. Therapeutics. 2025;2(3):11.
  6. [6]. Kargaran PK, et al. Scientific Reports. 2025;15(1). [IF: 3.9]
  7. [7]. Brescia M, et al. Stem Cell Reports. 2026;21(3):102816. [IF: 5.1]
  8. [8]. Ryu B, et al. BMB Reports. 2020;53(8):437-441. [IF: 4.778]